| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BoNT-IN-33 targets the light chain of botulinum neurotoxin A (BoNT/A LC). BoNT/A LC is a zinc-dependent endopeptidase that cleaves SNAP-25, a protein essential for synaptic vesicle fusion and neurotransmitter release. By inhibiting BoNT/A LC with an IC50 of 4.5 μM, BoNT-IN-33 blocks the proteolytic activity of the toxin, preventing SNAP-25 cleavage and subsequent neuromuscular paralysis. The compound is used as a tool to study BoNT biology and develop therapeutics for botulism.
|
|---|---|
| ln Vitro |
In vitro, BoNT-IN-33 inhibits BoNT/A LC activity with an IC50 of 4.5 μM. The compound is evaluated in enzyme activity assays using purified BoNT/A LC and peptide substrates that mimic the SNAP-25 cleavage site. Inhibition of BoNT/A LC proteolytic activity prevents SNAP-25 cleavage. These properties make BoNT-IN-33 a valuable tool for studying botulinum neurotoxin inhibition.
|
| ln Vivo |
In vivo, BoNT-IN-33 may be used in animal models of botulism to evaluate its ability to neutralize BoNT/A toxicity. By inhibiting BoNT/A LC, the compound could potentially prevent or reverse neurotoxin-induced paralysis. Specific animal model data and dosing regimens are available in the primary literature but are not detailed in the available sources.
|
| Enzyme Assay |
Not specifically documented for BoNT-IN-33. For BoNT/A LC inhibitors, cell-free enzyme assays typically measure the inhibition of BoNT/A LC endopeptidase activity using purified enzyme preparations and peptide substrates that mimic the SNAP-25 cleavage site. Fluorescence-based or mass spectrometry-based detection methods are used to quantify substrate cleavage. IC50 values are determined from concentration-response curves.
|
| Cell Assay |
In vitro cell-based assays for BoNT-IN-33 may include assessment of BoNT/A toxicity in neuronal cell models. SNAP-25 cleavage can be measured by Western blot or immunoassay to evaluate inhibition of BoNT/A LC activity in cells. Cell viability assays may assess protection from BoNT/A-mediated cytotoxicity. The compound is tested at concentrations around its IC50 of 4.5 μM.
|
| Animal Protocol |
In vivo studies with BoNT-IN-33 are conducted in animal models of botulism where BoNT/A is administered to induce paralysis. The compound may be administered prophylactically or therapeutically to evaluate its ability to neutralize BoNT/A toxicity. Endpoints include survival, assessment of muscle paralysis, and evaluation of BoNT/A LC inhibition in tissues. Dosing regimens are detailed in the primary literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for BoNT-IN-33 are not extensively documented in the available literature. The compound is a small molecule with molecular weight 398.5 and formula C25H26N4O. It appears as a white to off-white solid powder. Detailed PK parameters such as half-life, bioavailability, and clearance have not been reported in the available sources.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for BoNT-IN-33 are not provided in the available literature. As a research compound, it is not intended for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound. The compound is supplied for research purposes only.
|
| References | |
| Additional Infomation |
BoNT-IN-33 is also known as BoNTIN33, compound 33, and BoNT-IN-2. The IUPAC name is 7-{[4-(Dimethylamino)phenyl][(6-methylpyridin-2-yl)amino]methyl}-2-methylquinolin-8-ol. The molecular formula is C25H26N4O with a molecular weight of 398.5. It is a potent inhibitor of botulinum neurotoxin A light chain with an IC50 of 4.5 μM.
|
| Exact Mass |
398.2107
|
|---|---|
| CAS # |
354784-03-5
|
| Appearance |
White to off-white solid powder
|
| Synonyms |
BoNTIN33; compound 33; BoNT inhibitor
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~12.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
